| Bioactivity | (S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX)[1]. | ||||||||||||
| Target | β/α-1 adrenergic receptor | ||||||||||||
| Invitro | The β-receptor blocking activity of (S)-Carvedilol is about 100 times greater than that of (R)-Carvedilol, whereas both enantiomers show equipotent potency as α-blockers[1].(S)-Carvedilol significantly attenuates Doxorubicin (DOX)-induced cell death, apoptotic morphological changes, decrease the mitochondrial membrane potential and oxidative stress responses by increasing the superoxide dismutase and catalase activities, and decreasing malondialdehyde contents and reactive oxygen species levels via the PI3K/AKT/eNO synthase pathway in vitro[1].(S)-Carvedilol treatment significantly upregulates the expression levels of p-eNOS in HUVECs[1]. | ||||||||||||
| Name | (S)-Carvedilol | ||||||||||||
| CAS | 95094-00-1 | ||||||||||||
| Formula | C24H26N2O4 | ||||||||||||
| Molar Mass | 406.47 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Wu T, et al. Protective effects of S-carvedilol on doxorubicin-induced damages to human umbilical vein endothelial cells and rats. J Appl Toxicol. 2019 Aug;39(8):1233-1244. |
(S)-Carvedilol
CAS: 95094-00-1 F: C24H26N2O4 W: 406.47
(S)-Carvedilol, the S-enantiomer of Carvedilol, is a non-selective β/α-1 blocker. (S)-Carvedilol exerts protection aga
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.